Stamakort
Stamakort is a complex peptide bioregulator preparation derived from gastric mucosal tissue, developed for targeted support of stomach function and gastrointestinal mucosal integrity. Research indicates potential gastroprotective effects including reduced mucosal inflammation, enhanced epithelial repair, and improved gastric secretory function in aging models.
Stamakort is a complex peptide preparation classified as a cytomedine — a class of tissue-specific bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson.
Overview
Stamakort was developed as part of a broader program of organ-specific peptide bioregulators at the St. Petersburg Institute of Bioregulation and Gerontology. The underlying theory, advanced by Khavinson (2005), proposes that tissue-derived peptide complexes can restore gene expression patterns disrupted by aging or disease, returning cells to more youthful functional states. Each cytomedine targets a specific tissue type — in Stamakort's case, gastric mucosal epithelium.
The preparation is obtained through controlled extraction from animal stomach tissue, yielding a standardized low-molecular-weight peptide fraction. This approach follows the same methodology used to produce other established cytomedines such as Thymalin (thymus), Retinalamin (retina), and Cortexin (brain cortex), all of which have been studied extensively in Russian clinical settings.
Mechanism of Action
Stamakort's proposed mechanism follows the general bioregulatory peptide model established by Khavinson and colleagues. Short peptides in the complex are thought to penetrate cell membranes and interact directly with DNA, modulating gene expression in a tissue-specific manner. In gastric tissue, this is hypothesized to result in:
- Enhanced mucosal barrier function through upregulation of mucin-producing goblet cells and tight junction proteins in the gastric epithelium
- Reduced inflammatory signaling by modulating cytokine expression in the gastric mucosa, particularly pro-inflammatory mediators involved in gastritis progression
- Improved epithelial turnover by normalizing the proliferation-differentiation balance in gastric stem cells located in the glandular crypts
- Restored secretory function through regulation of parietal cell and chief cell activity, supporting appropriate acid and pepsinogen production
The tissue-specific targeting observed across the cytomedine class suggests that the peptide mixtures contain sequences recognized by chromatin regulatory elements unique to each tissue type, consistent with Khavinson's epigenetic regulation hypothesis (Khavinson et al., 2021).
Reconstitution Calculator
Reconstitution Calculator
Calculate your peptide dosing
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Gastric Mucosal Protection
The primary research interest in Stamakort relates to its potential gastroprotective properties. Within the bioregulatory peptide framework, gastric-targeted peptides are expected to enhance the mucosal defense mechanisms that protect the stomach lining from acid, pepsin, and external irritants. Preclinical models of gastric injury have been used to evaluate cytomedine effects on mucosal integrity, though published data specific to Stamakort remains limited compared to the more extensively studied single-peptide bioregulators.
The general principle of peptide-mediated gastroprotection is supported by broader research showing that endogenous peptides play critical roles in gastric mucosal defense. For example, trefoil factors (TFF peptides) are well-established regulators of mucosal repair, and their expression patterns change significantly with aging.
Aging and Gastric Function
Age-related changes in gastric function include reduced mucosal blood flow, decreased mucus and bicarbonate secretion, impaired epithelial regeneration, and increased susceptibility to ulceration. Khavinson's bioregulatory approach posits that organ-specific peptide complexes can partially reverse these changes by reactivating silenced genes in aging cells. This concept was demonstrated for other cytomedines: Khavinson et al. (2012) showed that peptides tissue-specifically stimulate cell differentiation during aging, with older cells showing greater responsiveness to bioregulatory peptide treatment than younger cells.
Applied to gastric tissue, this suggests Stamakort may be most relevant in age-related gastric conditions where mucosal defense mechanisms have deteriorated.
Gastrointestinal Inflammation
The anti-inflammatory properties attributed to bioregulatory peptides extend to the gastrointestinal context. Chronic gastritis, whether driven by Helicobacter pylori infection or autoimmune processes, involves sustained inflammatory signaling that damages the mucosal barrier. Bioregulatory peptides have been shown to modulate NF-kB and related inflammatory pathways in other tissue contexts (Ashapkin et al., 2020), and similar mechanisms are hypothesized for Stamakort in gastric tissue.
Safety Profile
Stamakort, as a complex peptide preparation composed of naturally occurring low-molecular-weight peptides, is generally considered to have a favorable safety profile consistent with other cytomedines in the Khavinson series. These preparations have been used in Russian clinical practice for decades without reports of significant adverse effects. The peptide components are rapidly metabolized through normal proteolytic pathways and are not expected to accumulate in tissues.
However, formal toxicology studies and controlled human clinical trials published in international peer-reviewed journals remain limited. As with all bioregulatory peptides, individuals with active gastrointestinal malignancies should exercise caution, as the growth-promoting effects on epithelial tissue are not fully characterized in oncologic contexts.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Route
- Oral
Molecular Structure
- Formula
- Not applicable (polypeptide complex)
- CAS
- Not available
Research Protocols
oral
Administered via oral.
Quality Indicators
What to look for
- Human clinical trials conducted
- Well-established safety profile
- Naturally occurring compound
Frequently Asked Questions
References (4)
- [2][Khavinson VK et al. (2012). Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med (2012)
- [1][Khavinson VK (2005). Peptides and ageing. Neuro Endocrinol Lett (2005)
- [3][Ashapkin V et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep (2020)
- [4][Khavinson VK et al. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules (2021)
SS-31
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that stabilizes cardiolipin to improve ATP production and reduce reactive oxygen species, with research applications in mitochondrial myopathy, heart failure, diabetes, and inflammatory diseases.
Substance P
Substance P is an 11-amino acid tachykinin neuropeptide that functions as a key neurotransmitter in pain transmission, neurogenic inflammation, and mood regulation through the neurokinin-1 (NK1) receptor. It is one of the most extensively studied neuropeptides and the target of NK1 receptor antagonists used clinically as antiemetics.